3tfp: Difference between revisions
No edit summary |
No edit summary |
||
Line 1: | Line 1: | ||
[[ | ==Crystal Structure of Dehydrosqualene Synthase (CrtM) from S. aureus Complexed with BPH-1162== | ||
<StructureSection load='3tfp' size='340' side='right' caption='[[3tfp]], [[Resolution|resolution]] 2.00Å' scene=''> | |||
== Structural highlights == | |||
<table><tr><td colspan='2'>[[3tfp]] is a 1 chain structure with sequence from [http://en.wikipedia.org/wiki/Staphylococcus_aureus Staphylococcus aureus]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3TFP OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=3TFP FirstGlance]. <br> | |||
</td></tr><tr><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=03L:2-({2-CHLORO-6-[(2,4-DICHLOROPHENYL)SULFANYL]BENZYL}CARBAMOYL)BENZOIC+ACID'>03L</scene>, <scene name='pdbligand=MG:MAGNESIUM+ION'>MG</scene><br> | |||
<tr><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">crtM ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=1280 Staphylococcus aureus])</td></tr> | |||
<tr><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=3tfp FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3tfp OCA], [http://www.rcsb.org/pdb/explore.do?structureId=3tfp RCSB], [http://www.ebi.ac.uk/pdbsum/3tfp PDBsum]</span></td></tr> | |||
<table> | |||
<div style="background-color:#fffaf0;"> | |||
== Publication Abstract from PubMed == | |||
Double whammy! Small molecules that inhibit Staphylococcus aureus dehydrosqualene synthase (CrtM) or host squalene synthase (SQS) are of interest as novel, innate immunity-based therapeutics, blocking virulence or stimulating antibacterial neutrophil extracellular trap (NET) formation. The discovery of leads that do both represents a new route to treating staph infections. | |||
Dual dehydrosqualene/squalene synthase inhibitors: leads for innate immune system-based therapeutics.,Lin FY, Zhang Y, Hensler M, Liu YL, Chow OA, Zhu W, Wang K, Pang R, Thienphrapa W, Nizet V, Oldfield E ChemMedChem. 2012 Apr;7(4):561-4. doi: 10.1002/cmdc.201100589. Epub 2012 Jan 30. PMID:22290830<ref>PMID:22290830</ref> | |||
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |||
</div> | |||
== References == | |||
<references/> | |||
__TOC__ | |||
</StructureSection> | |||
== | |||
< | |||
[[Category: Staphylococcus aureus]] | [[Category: Staphylococcus aureus]] | ||
[[Category: Lin, F Y.]] | [[Category: Lin, F Y.]] |
Revision as of 08:40, 5 June 2014
Crystal Structure of Dehydrosqualene Synthase (CrtM) from S. aureus Complexed with BPH-1162Crystal Structure of Dehydrosqualene Synthase (CrtM) from S. aureus Complexed with BPH-1162
Structural highlights
Publication Abstract from PubMedDouble whammy! Small molecules that inhibit Staphylococcus aureus dehydrosqualene synthase (CrtM) or host squalene synthase (SQS) are of interest as novel, innate immunity-based therapeutics, blocking virulence or stimulating antibacterial neutrophil extracellular trap (NET) formation. The discovery of leads that do both represents a new route to treating staph infections. Dual dehydrosqualene/squalene synthase inhibitors: leads for innate immune system-based therapeutics.,Lin FY, Zhang Y, Hensler M, Liu YL, Chow OA, Zhu W, Wang K, Pang R, Thienphrapa W, Nizet V, Oldfield E ChemMedChem. 2012 Apr;7(4):561-4. doi: 10.1002/cmdc.201100589. Epub 2012 Jan 30. PMID:22290830[1] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. References
|
|